权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Phosphoglycerate mutase 5 (PGAM5) in the regulation of hepatic lipid metabolism and carcinogenesis

磷酸甘油酸变位酶 5 (PGAM5) 在肝脏脂质代谢和癌变调节中的作用

基本信息

批准号：
10579216
负责人：
Andrea Noel Johnston
金额：
$ 22.18万
依托单位：
LOUISIANA STATE UNIV A&M COL BATON ROUGE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-03-01 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10579216
关键词：
3-Dimensional Affect Bioenergetics Biogenesis Biological Markers Brown Fat Cell Death Cells Cellular Spheroids Colon Carcinoma Complex Data Defect Development Doctor of Philosophy Fatty Liver Fluorouracil Functional disorder Gene Expression Genetic Transcription Genus Hippocampus Glycolysis HepG2 Hepatic Hepatic Stellate Cell Hepatic Tissue Hepatocyte High Fat Diet Homeostasis Human Hybrid Cells In Vitro Inflammatory Injury Knock-out Knockout Mice Left Link Lipids Liver Liver Mitochondria Liver diseases Malignant Epithelial Cell Malignant Neoplasms Malignant neoplasm of liver Measures Mediating Mediator Metabolic Pathway Metabolism Mitochondria Mitochondrial Membrane Protein Modeling Mus Nutrient Obesity Obesity Epidemic Outcome Oxidants Oxidation-Reduction Oxidative Phosphorylation Pathogenesis Pathway interactions Phosphoglycerate Mutase Phosphoric Monoester Hydrolases Population Primary carcinoma of the liver cells Production Proteins Publications Rattus Reactive Oxygen Species Regulation Research Respiration Risk Factors Role Serine Serum Survival Rate Testing Therapeutic Thermogenesis Threonine Treatment outcome Triglycerides anticancer research bioprinting carcinogenesis comparison control diet-induced obesity fatty acid oxidation glucose tolerance hepatocellular carcinoma cell line in vivo insight insulin sensitivity interest knock-down lipid biosynthesis lipid metabolism lipine live cell imaging metabolic phenotype mitochondrial dysfunction mitochondrial metabolism molecular imaging new therapeutic target non-alcoholic fatty liver disease nonalcoholic steatohepatitis overexpression pre-clinical prevent respiratory single cell sequencing single-cell RNA sequencing survival outcome therapeutic target transcriptomic profiling tumor growth tumorigenesis

项目摘要

Summary: PGAM5 in the regulation of hepatic lipid metabolism and carcinogenesis (PI: Andrea Johnston, DVM, PhD). The broad objective of this project is to determine whether changes in mitochondrial metabolism mechanistically influence the transition from non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). NAFLD is emerging as a leading cause of HCC. HCC survival outcomes are poor. Defining the bioenergetic pathophysiology of NAFLD and its progression to HCC will identify new biomarkers and therapeutic targets. The mitochondrial membrane protein phosphoglycerate mutase 5 (PGAM5) regulates an array of mitochondrial homeostatic pathways. Recent research shows that depletion of PGAM5 prevents both high fat diet (HFD) induced obesity and the progression of HCC. The proposed research will test the hypothesis that distinct mitochondrial metabolic pathways are responsible for these effects. A liver specific knockout mouse will be generated to determine whether hepatocyte specific loss of PGAM5 will inhibit steatosis in a HFD model. Single cell RNA sequencing of a human HCC cell line will determine if PGAM5 depletion alters gene expression associated with hepatic lipid metabolism. HCC spheroids will be used to characterize how loss of PGAM5 modulates mitochondrial respiration and glycolysis in a steatosis model. Two specific aims are proposed: Aim 1 will determine whether PGAM5 knockout inhibits hepatocellular steatosis. Aim 2 will determine whether PGAM5 deletion alters mitochondrial metabolism in HCC leading to increased reactive oxygen species production.

PGAM5在肝脏脂质代谢调控及癌变中的作用 (PI：Andrea约翰斯顿，兽医学博士，哲学博士）。这个项目的主要目标是确定线粒体代谢的变化是否机制上影响从非酒精性脂肪肝（NAFLD）到肝细胞癌（HCC）。NAFLD正在成为HCC的主要原因。HCC生存率结果很差。定义NAFLD的生物能量病理生理学及其进展 HCC将发现新的生物标志物和治疗靶点。线粒体膜蛋白磷酸甘油酸酯β 5（PGAM5）调节一系列线粒体稳态途径。最近的研究表明，PGAM5的消耗可以防止高脂饮食（HFD）诱导的肥胖和HCC的进展。这项拟议中的研究将检验这一假设，线粒体代谢途径是造成这些效应的原因。肝脏特异性基因敲除将产生小鼠以确定PGAM5的肝细胞特异性损失是否将抑制 HFD模型中的脂肪变性。人HCC细胞系的单细胞RNA测序将确定 PGAM5耗竭改变与肝脏脂质代谢相关的基因表达。HCC 球状体将用于表征PGAM5的缺失如何调节线粒体呼吸和糖酵解。提出了两个具体目标：目标1将确定 PGAM5敲除抑制肝细胞脂肪变性。目标2将确定PGAM5缺失是否改变HCC中的线粒体代谢，导致活性氧产生增加。